Recurrent venous thromboembolism is more common in people with granulomatosis with polyangiitis than among individuals in the general population who had an unprovoked first event, US researchers report in Rheumatology Advances in Practice.

medwireNews : The indication for mepolizumab should be extended to include eosinophilic granulomatosis with polyangiitis (EGPA), recommends the EMA.

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients [ read more ].

The authors report two patients with ulcerative lesions resembling pyoderma gangrenosum that were the presenting sign of granulomatosis with polyangiitis and propose an approach to differentiate the two [read more ]. Genovese G et al. Rheumatol Int 2018; Advance online publication. doi: 10.1007/s00296-018-4035-z

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.

Puéchal X et al. Rheumatology (Oxford) 2018: key117. doi: 10.1093/rheumatology/key117

Wallace ZS et al. Ann Rheum Dis 2018. doi: 10.1136/annrheumdis-2018-213452

Sequential treatment with rituximab followed by mepolizumab may be a promising strategy to treat the systemic and respiratory manifestations of eosinophilic granulomatosis with polyangiitis, suggest findings from an observational study.

An international group of experts has developed and validated classification criteria for eosinophilic granulomatosis with polyangiitis, GPA, and microscopic polyangiitis.

Neurologic and ocular manifestations are common among people with ANCA-associated vasculitis but vary by disease type, show data from the Vasculitis Clinical Research Consortium reported at the ACR Convergence 2021 virtual meeting.

Rituximab is well tolerated and shows good efficacy in children with granulomatosis with polyangiitis or microscopic polyangiitis, global phase 2a study findings indicate.

Patients who have granulomatosis with polyangiitis and high blood eosinophil levels at diagnosis are more likely to have severe disease and skin and neurological involvement than those with lower levels, French study findings indicate.

The complement 5a receptor inhibitor may now be given to adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

Avacopan is recommended for the treatment of two types of ANCA-associated vasculitis – granulomatosis with polyangiitis and microscopic polyangiitis – at a dose of 30 mg twice daily, given in combination with standard therapy including glucocorticoids.

A case report published in the Annals of the Rheumatic Diseases describes the experience of a rituximab-treated patient with ANCA-associated vasculitis who developed severe COVID-19.

Understand the need for effective remission maintenance strategies for granulomatosis with polyangiitis Be able to explain current trends in remission maintenance strategies for granulomatosis with polyangiitis.